Compagnie Lombard Odier SCmA Has $10.48 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Compagnie Lombard Odier SCmA trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 10.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 134,810 shares of the medical device company’s stock after selling 16,473 shares during the period. Compagnie Lombard Odier SCmA’s holdings in DexCom were worth $10,484,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Crossmark Global Holdings Inc. raised its position in DexCom by 1.0% during the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after buying an additional 182 shares during the period. GPS Wealth Strategies Group LLC increased its position in DexCom by 13.2% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock worth $123,000 after purchasing an additional 185 shares during the last quarter. Peterson Wealth Services increased its position in DexCom by 7.1% in the 4th quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock worth $236,000 after purchasing an additional 201 shares during the last quarter. Magnolia Capital Advisors LLC increased its position in DexCom by 2.6% in the 4th quarter. Magnolia Capital Advisors LLC now owns 8,198 shares of the medical device company’s stock worth $638,000 after purchasing an additional 210 shares during the last quarter. Finally, Riverview Trust Co increased its position in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,342 shares of company stock worth $3,628,069. 0.30% of the stock is currently owned by company insiders.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $84.09 on Friday. The business has a 50 day moving average price of $82.11 and a 200 day moving average price of $75.19. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a market cap of $32.85 billion, a price-to-earnings ratio of 50.35, a PEG ratio of 2.26 and a beta of 1.14. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. Research analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Sanford C. Bernstein upped their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. JPMorgan Chase & Co. upped their target price on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Finally, Wells Fargo & Company upped their price target on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $98.41.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.